Floatz logo

dn-101

Chronic Liver Disease (CLD)

Chulalongkorn UniversitySmall moleculePhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Chronic Liver Disease (CLD) cohort.

Asset / SponsorPhaseRating
ERGOCALCIFEROLUM
Chulalongkorn University
Phase 4B

Same molecule, other indications

dn-101 is also rated in:

Friedreich AtaxiaDormant
B
Indicative ·
62 / 100
View asset →
PsoriasisDormant
B
Indicative ·
59 / 100
View asset →
Facial AngiofibromaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →